(Q41601558)

4 October 2017

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib (English)

1 reference

chronic lymphocytic leukemia

4 October 2017

0 references

1 reference

1 reference

9

Hagop Kantarjian

1 reference

4 October 2017

5

Alessandra Ferrajoli

1 reference

4 October 2017

4

Zeev Estrov

1 reference

4 October 2017

3

William Wierda

1 reference

4 October 2017

11

Susan O'Brien

1 reference

4 October 2017

2

Michael Keating

1 reference

4 October 2017

1

Preetesh Jain

1 reference

4 October 2017

10

Jan Burger

1 reference

4 October 2017

8

Danelle James

1 reference

4 October 2017

Nitin Jain

6

1 reference

4 October 2017

Binsah George

series ordinal

7

1 reference

4 October 2017

language of work or name

English

0 references

publication date

8 January 2015

1 reference

4 October 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Blood

1 reference

4 October 2017

125

1 reference

4 October 2017

13

1 reference

4 October 2017

2062-2067

1 reference

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

4 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467871

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467871

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467871

Targeting Bruton's tyrosine kinase in B cell malignancies

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467871

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467871

B-cell receptor signaling as a driver of lymphoma development and evolution

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467871

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467871

10.1182/BLOOD-2014-09-603670

6 June 2018

Identifiers

DOI

1 reference

4 October 2017

1 reference

4 October 2017

PubMed publication ID

25573991

1 reference